Preliminary Third Quarter 2020 Revenue Expected to be $22.4 to $22.8 Million MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 15, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced preliminary third quarter
MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 9, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it will release third quarter 2020 financial results on November 2, 2020 .
MENLO PARK, Calif. & BERLIN --(BUSINESS WIRE)--Oct. 2, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced it closed the previously announced transaction to acquire Fiagon AG Medical Technologies , a
Novel navigation technology and recently FDA-cleared sinuplasty balloon expand Intersect ENT’s commercial product portfolio Extends Intersect ENT’s footprint in U.S. and European ENT physicians’ offices MENLO PARK, Calif. and BERLIN --(BUSINESS WIRE)--Sep. 15, 2020-- Intersect ENT, Inc.
MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 4, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the second quarter ended June 30, 2020 .
MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 22, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it will release second quarter 2020 financial results on August 4, 2020 .
MENLO PARK, Calif. --(BUSINESS WIRE)--May 26, 2020-- Intersect ENT, Inc. (Nasdaq: XENT ), today announced that management will participate in a virtual fireside chat at the William Blair 40 th Annual Growth Stock Conference . The fireside chat will take place on Thursday, June 11, 2020 at 8:00 a.m.
